natgillin/translations-raw huggingface dataset:
Special precautions to be taken by the person administering the veterinary medicinal product to animals 
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo - Tilmikozin lahko povzroči draženje.
4.2 Indications for use, specifying the target species Pigs: Prevention and treatment of respiratory disease caused by Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae, Pasteurella multocida and other organisms sensitive to tilmicosin Rabbits: Prevention and treatment of respiratory disease caused by Pasteurella multocida and Bordetella bronchiseptica, susceptible to tilmicosin. 
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Prašiči: preprečevanje in zdravljenje bolezni dihal, ki jih povzročajo Actinobacillus pleuropneumoniae, Mycoplasma hyopneumoniae, Pasteurella multocida in drugi organizmi, ki so občutljivi za tilmikozin.
Administer in the feed at a dose of 8 to 16 mg/kg body weight/day of tilmicosin (equivalent to 200 to 400 ppm in the feed) for a period of 15 to 21 days. 
Dajajte v krmno mešanico 15 do 21 dni v odmerku 8 do 16 mg tilmikozina/kg telesne mase/dan (enakovredno 200 do 400 ppm v krmni mešanici).
Administer in the feed at 12 mg/kg body weight/day of tilmicosin (equivalent to 200 ppm in the feed) for 7 days. 
Dajanje v krmno mešanico 7 dni s koncentracijo 12 mg tilmikozina/kg telesne mase/dan (enakovredno 200 ppm v krmni mešanici).
Marketing Authorisation Holders. 
IMETNIK DOVOLJENJA ZA PROMET {Izpolni država članica}
A preformed block bottomed 1 kg bag constructed using a paper/polyethylene/aluminium/polyethylene/paper laminate either stitched closed or heat-sealed Not all pack sizes may be marketed. 
1. vreče iz polietilena/poliamida/polietilena (notranja plast) z 10 kg zdravila ali 2. vreče z oblikovanim kvadrastim dnom iz papirja/polietilena/aluminija/polietilena/papirja z 1 kg zdravila, ki so zašite ali toplotno zavarjene.
6.5 Nature and composition of immediate packaging Products containing 40 and 100g tilmicosin/kg are packed in either: 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi Za zdravila, ki vsebujejo 40 in 100 g tilmikozina/kg:
Administer in the feed at a dose of 8 to 16 mg/kg body weight/day of tilmicosin activity (equivalent to 200 to 400 ppm in the feed) for a period of 15 to 21 days. 
Dajajte v krmno mešanico15 do 21 dni v odmerku tilmikozina 8 do 16 mg/kg telesne mase/dan (enakovredno 200 do 400 ppm v krmni mešanici).
Pulmotil G 40 AMV Premix for medicated feeding stuff 
Pulmotil G 40 AMV predmešanica za zdravilno krmno mešanico
Pulmotil G 100 AMV Premix for medicated feeding stuff 
Pulmotil G 100 AMV predmešanica za zdravilno krmno mešanico
Pulmotil Prämix 20% Premix for medicated feeding stuff 
Pulmotil Prämix 20% predmešanica za zdravilno krmno mešanico prašiči, kunci
Pulmotil G 200 premix Premix for medicated feeding stuff 
Pulmotil G 200 premix predmešanica za zdravilno krmno mešanico
Pulmotil G40 premix Premix for medicated feeding stuff 
Pulmotil G40 premix predmešanica za zdravilno krmno mešanico
Pulmotil G100 premix Premix for medicated feeding stuff 
Pulmotil G100 Premix predmešanica za zdravilno krmno mešanico
Pulmotil G100 Premix Premix for medicated feeding stuff 
Pulmotil G100 premix predmešanica za zdravilno krmno mešanico
Pulmotil G200 premix Premix for medicated feeding stuff 
Pulmotil G200 Premix predmešanica za zdravilno krmno mešanico
Pulmotil G200 Premix Premix for medicated feeding stuff 
Pulmotil G200 premix predmešanica za zdravilno krmno mešanico
2 kg Pulmotil 100Vet Premix/tonne 
2 kg Pulmotil 100 Vet Premix/tono
Rabbits 
Ciper
Pulmotil 40 VET Premix Premix for medicated feeding stuff 
Pulmotil 40 VET Premix predmešanica za zdravilno krmno mešanico
Absorption: When administered orally to rabbits at a dose of 12 mg tilmicosin/kg b.w. 
Absorpcija: Pri kuncih se tilmikozin po peroralnem dajanju odmerka 12 mg/kg telesne mase v enem odmerku hitro absorbira.
PHARMACEUTICAL PARTICULARS 6.1 List of excipients 
6.5 Vrsta ovojnine in vsebina
The European Commission granted a marketing authorisation valid throughout the European Union for Byetta on 20 November 2006. 
Evropska komisija je dovoljenje za promet z zdravilom Byetta, veljavno po vsej Evropski uniji, odobrila dne 20. novembra 2006.
The first dose of the day is administered within the one hour before the morning meal, and the second dose within the one hour before the evening meal. 
Prvi odmerek v dnevu se daje eno uro pred jutranjim obrokom, drugi pa eno uro pred večernim obrokom.
Byetta exenatide 
Byetta eksenatid
Byetta should never be given after a meal. 
Zdravilo Byetta se ne sme nikoli dati po obroku.
The full EPAR for Byetta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Byetta je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Little or no effect was seen with placebo. 
Pri placebu je bilo opaziti majhen ali ničen učinek.
Patients were also taking either metformin or pioglitazone, or a combination of both. 
Bolniki so prav tako jemali bodisi metformin ali pioglitazon ali kombinacijo obojega.
Other information about Byetta: 
Druge informacije o zdravilu Byetta:
At the start of the studies, the patients' HbA1c levels were around 8.4%. 
Na začetku študij so ravni HbA1c pri bolnikih znašale približno 8,4 %.
This document is a summary of the European public assessment report (EPAR) for Byetta. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Byetta.
This helps with the control of blood glucose levels. 
To pomaga pri uravnavanje ravni glukoze.
It is available as prefilled injection pens that provide either 5 or 10 micrograms of exenatide in each dose. 
Na voljo je v obliki napolnjenega injekcijskega peresnika, ki vsebuje bodisi 5 ali 10 mikrogramov eksenatida v posameznem odmerku.
For more information about treatment with Byetta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Byetta preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
The CHMP decided that Byetta's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Byetta večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
Treatment with Byetta should start at a dose of 5 micrograms twice a day for at least a month. 
Zdravljenje z zdravilom Byetta se začne z odmerkom 5 mikrogramov dvakrat na dan najmanj en mesec.
This means that it acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin released by the pancreas in response to food. 
To pomeni, da deluje na enak način kot inkretini (v črevesu proizvedeni hormoni), ki povečujejo količino insulina, ki ga kot odziv na hrano izloči trebušna slinavka.
Byetta is used to treat type 2 diabetes. 
Zdravilo Byetta se uporablja za zdravljenje sladkorne bolezni tipa 2.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Byetta. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Byetta, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Byetta was as effective as injected insulin. 
Zdravilo Byetta je bilo enako učinkovito kot vbrizgan insulin.
What benefit has Byetta shown during the studies? 
Kakšne koristi je zdravilo Byetta izkazalo med študijami?
Patients being treated with Byetta should continue to follow their diet and exercise plans. 
Bolniki, ki se zdravijo z zdravilom Byetta, bi morali nadaljevati z začrtanim programom prehrane in telesne vadbe.
It can be used with metformin, sulphonylureas, thiazolidinediones, metformin and a sulphonylurea, or metformin and a thiazolidinedione. 
Uporablja se lahko v kombinaciji z metforminom, sulfonilsečninami in tiazolidindioni, metforminom in sulfonilsečnino ali metforminon in tiazolidindionom.
Byetta has been studied in eight main studies involving a total of around 3,000 patients whose blood glucose was not adequately controlled with other antidiabetes medicines. 
Zdravilo Byetta so poučevali v osmih glavnih študijah, ki so vključevale okrog 3 000 bolnikov, pri katerih glukoza v krvi ni bila zadostno nadzorovana z drugimi zdravili proti sladkorni bolezni.
Byetta must not be used in people who are hypersensitive (allergic) to exenatide or any of the other ingredients. 
Zdravila Byetta ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) eksenatid ali katero koli drugo sestavino zdravila.
Adding Byetta to metformin or pioglitazone is not associated with this risk. 
Uporaba zdravila Byetta z metforminom ali pioglitazonom s tem tveganjem ni povezana.
What is the risk associated with Byetta? 
Kakšna tveganja so povezana z zdravilom Byetta?
Byetta can also be given to patients taking basal insulin (long-acting insulin such as insulin glargine) with or without metformin and/or pioglitazone (a thiazolidinedione) and whose blood glucose levels are not adequately controlled with these medicines. 
Zdravilo Byetta se lahko daje tudi bolnikom, ki jemljejo bazalni insulin (insulin z dolgotrajnim delovanjem kot insulin glargin) z metforminom ali brez njega in/ali pioglitazonom (tiazolidinedion) in pri katerih ravni glukoze v krvi niso zadostno nadzorovane s temi zdravili.
Byetta was more effective than placebo in reducing the levels of HbA1c when used in combination with other antidiabetes medicines. 
Zdravilo Byetta je bilo v primerjavi s placebom učinkovitejše pri nižanju ravni HbA1c, kadar so ju uporabljali v kombinaciji z drugimi zdravili proti sladkorni bolezni.
The pen has a user manual. 
Peresniku je priložen priročnik za uporabo.
For the full list of all side effects reported with Byetta, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Byetta, glejte navodilo za uporabo.
A dose higher than 10 micrograms twice a day is not recommended. 
Odmerek se lahko nato poveča na 10 mikrogramov dvakrat na dan. Odmerek, ki presega 10 mikrogramov dvakrat na dan, ni priporočen.
When adding Byetta to a sulphonylurea or basal insulin, the doctor may need to reduce the dose of the sulphonylurea or basal insulin because there is a risk of hypoglycaemia (low blood sugar levels). 
Kadar se zdravilo Byetta doda sulfonilsečnini ali bazalnemu insulinu, mora zdravnik zmanjšati njun odmerek, ker obstaja tveganje za pojav hipoglikemije (nizke ravni sladkorja v krvi).
It is used together with other antidiabetes medicines in patients whose blood glucose (sugar) levels are not adequately controlled with the maximum tolerated doses of the other medicines. 
Uporablja se skupaj z drugimi zdravili proti sladkorni bolezni pri bolnikih, pri katerih ravni glukoze (sladkorja) v krvi niti z uporabo največjih odmerkov drugih zdravil, ki jih bolnik še prenaša, ni mogoče ustrezno nadzorovati.
Why has Byetta been approved? 
Zakaj je bilo zdravilo Byetta odobreno?
Byetta was more effective than placebo when it was given as add-on to insulin glargine (with or without other antidiabetes medications), as Byetta decreased HbA1c by an average of 1.7% compared with an average of 1.0% in patients taking placebo. 
Zdravilo Byetta je bilo učinkovitejše od placeba, ko je bilo dodano insulinu glargin (z drugimi zdravili proti sladkorni bolezni ali brez njih), saj se je pri zdravilu Byetta raven HbA1c v povprečju znižala za 1,7 % v primerjavi s povprečnim znižanjem za 1,0 % pri bolnikih, ki so jemali placebo.
Two further studies compared adding Byetta or an insulin to metformin and sulphonylureas. 
V drugih dveh študijah so primerjali dodajanje zdravila Byetta ali insulina metforminu in sulfonilsečninam.
In one study, Byetta was compared with insulin glargine in 456 patients and in the other study it was compared with biphasic insulin in 483 patients. 
V eni študiji so zdravilo Byetta pri 456 bolnikih primerjali z insulinom glargin, v drugi študiji pa so zdravilo Byetta pri 483 bolnikih primerjali z dvofaznim insulinom.
In studies, the most common side effects with Byetta (seen in more than 1 patient in 10) were hypoglycaemia (when Byetta was used with sulphonylurea with or without metformin), nausea (feeling sick), vomiting and diarrhoea. 
Najpogostejši neželeni učinki zdravila Byetta (opaženi pri več kot 1 od 10 bolnikov) so hipoglikemija (ko je bilo zdravilo Byetta uporabljeno s sulfonilsečnino z metforminom ali brez njega), navzeja (slabost), bruhanje in driska.
The active substance in Byetta, exenatide, is an ‘incretin mimetic'. 
Zdravilna učinkovina zdravila Byetta, eksenatid, je „mimetik inkretina“.
In five of the studies, Byetta was compared with placebo (a dummy treatment), as an add-on to metformin (336 patients), sulphonylureas with or without metformin (1,110 patients) or thiazolidinediones with or without metformin (398 patients). 
V petih študijah so zdravilo Byetta kot dodatek k metforminu (336 bolnikov), sulfonilsečninam z metforminom ali brez njega (1 110 bolnikov) ali tiazolidindionom z metforminom ali brez njega (398 bolnikov) primerjali s placebom (zdravilom brez zdravilne učinkovine).
In another study involving 259 patients, Byetta was compared with placebo, as an add-on to insulin glargine. 
V naslednji študiji, ki je vključevala 259 bolnikov, so zdravilo Byetta kot dodatek insulinu glargin primerjali s placebom.
Byetta is a solution for injection that contains the active substance exenatide. 
Zdravilo Byetta je raztopina za injiciranje, ki vsebuje zdravilno učinkovino eksenatid.
When added to thiazolidinediones with or without metformin, the 10-microgram dose of Byetta reduced HbA1c levels by an average of 0.74% after 16 weeks and 0.84% after 26 weeks. 
Ko je bilo zdravilo Byetta dodano tiazolidindionom z metforminom ali brez njega so se pri 10-mikrogramskem odmerku ravni HbA1c po 16 tednih v povprečju znižale za 0,74 %, po 26 tednih pa za 0,84 %.
Byetta is given by injection under the skin of the thigh, the abdomen (tummy) or the upper arm, using the injection pen. 
Zdravilo Byetta se daje z injekcijo pod kožo stegna, trebuha ali nadlakti s pomočjo injekcijskega peresnika.
When it was added to metformin and/or sulphonylureas, the 5-microgram dose of Byetta decreased HbA1c levels by an average of 0.59% after 30 weeks, and the 10-microgram dose decreased them by an average of 0.89%. 
Ko je bilo zdravilo Byetta dodano metforminu in/ali sulfonilsečnini so se pri 5-mikrogramskem odmerku ravni HbA1c po 30 tednih v povprečju znižale za 0,59 %, pri 10-mikrogramskem odmerku pa za 0,89 %.
In the final study, the 10-microgram dose of Byetta decreased HbA1c by an average of 1.01% after 52 weeks, compared with an average of 0.86% with biphasic insulin. 
V zadnji študiji se je pri 10-mikrogramskem odmerku zdravila Byetta raven HbA1c po 52 tednih v povprečju znižala za 1,01 % v primerjavi s povprečnim znižanjem za 0,86 % pri uporabi dvofaznega insulina.
What is Byetta used for? 
Za kaj se zdravilo Byetta uporablja?
The 10-microgram dose of Byetta decreased HbA1c by an average of 1.13% after 26 weeks, compared with an average of 1.10% with insulin glargine. 
Pri 10-mikrogramskem odmerku zdravila Byetta se je po 26 tednih zdravljenja raven HbA1c v povprečju znižala za 1,13 % v primerjavi z 1,10 % povprečnim znižanjem pri uporabi insulina glargin.
How has Byetta been studied? 
Kako je bilo zdravilo Byetta raziskano?
What is Byetta? 
Kaj je zdravilo Byetta?
How does Byetta work? 
Kako zdravilo Byetta deluje?
How is Byetta used? 
Kako se zdravilo Byetta uporablja?
In addition, aggressive behaviour was observed. 
Poleg tega je bilo ugotovljeno agresivno vedenje.
Number of tablets per day 
Število tablet na dan
Reconcile tablets may be given with or without food. 
Tablete Reconcile se lahko dajejo s hrano ali brez nje.
Date of first authorisation: 08.07.2008 Date of last renewal: 13/07/2018 
Datum pridobitve dovoljenja za promet: 8. julij 2008 Datum zadnjega podaljšanja dovoljenja za promet: 13. julij 2018
Fluoxetine does not act as a sedative. 
Fluoksetin ne deluje kot sedacijsko sredstvo.
No effect on the reproductive capacity in male and female rats was noted. 
Ni bilo opaziti učinkov na reproduktivno sposobnost samcev in samic podgane.
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon. 
Če opazite kakršne koli stranske učinke, tudi tiste, ki še niso omenjeni v teh navodilih za uporabo, ali menite, da zdravilo ni pomagalo, obvestite svojega veterinarja.
Elimination studies in dogs have shown that 29.8% and 44% of the dose were excreted in urine and faeces, respectively by 14 days following dosing. 
Eliminacijske študije pri psih so kazale, da se je 29,8 % oziroma 44 % odmerkov izločilo prek urina in blata v 14. dneh po dajanju odmerka.
Fluoxetine is well absorbed after oral administration (approximately72%) and the absorption is not affected by feeding. 
Fluoksetin se dobro absorbira pri peroralni uporabi (približno 72 %), hrana pa ne vpliva na absorbcijo.
If no improvement is noted within 4 weeks, case management should be re-evaluated. 
Če po 4 tednih ne opazite izboljšanja, je potrebno ustreznost terapije ponovno proučiti.
If no improvement is noted within 4 weeks, consult your veterinary surgeon who will need to re-evaluate the dog's treatment. 
Če po 4 tednih ne opazite izboljšanja, se obrnite na svojega veterinarja, ki bo na ponovno pretehtal način zdravljenja psa.
Fluoxetine is largely metabolised by the P-450 enzyme system, although the precise isoform in dogs is unknown. 
Fluoksetin se večinoma presnavlja v encimskem sistemu P-450, vendar je natančna izo-oblika pri psih neznana.
EXP {month/year} Once opened use within 30 days. 
EXP {mesec/leto} Po odprtju uporabite v roku 30 dni.
- Decreased appetite (including anorexia); lethargy (very common). 
- Zmanjšan tek (vključno z anoreksijo); letargičnost (zelo pogosti).
Clinical improvement with the product is expected within 1 to 2 weeks. 
Klinično izboljšanje z uporabo zdravila se lahko pričakuje v 1 do 2 tednih.
Keep the bottle tightly closed in order to protect from moisture. 
Vsebnik shranjujte tesno zaprt, da se zaščiti pred vlago.
Do not use this veterinary medicinal product after the expiry date which is stated on the bottle. 
Ne uporabljajte zdravila za uporabo v veterinarski medicini po datumu izteka roka uporabnosti, navedenega na plastenki.
Therefore, fluoxetine should be used with caution with other veterinary medicinal products. 
Zato je treba fluoksetin v kombinaciji z drugimi veterinarskimi zdravili previdno uporabljati.
Laboratory studies in rats and rabbits have not produced any evidence of a teratogenic, foetotoxic or maternotoxic effect. 
Z laboratorijskimi študijami na podganah in kuncih niso bili dokazani teratogeni in fetotoksični učinki ter toksični učinki na mater.
Clinical studies have shown that a beneficial response has been demonstrated for up to 8 weeks treatment with fluoxetine. 
V kliničnih študijah se je izboljšanje pokazalo pri zdravljenju s fluoksetinom v trajanju do 8 tednov.
Fluoxetine lacks any significant affinity for neurotransmitter receptors, including the muscarinic cholinergic receptor, adrenergic receptors, or histaminergic H1 receptors, and does not have direct effects on the heart. 
Fluoksetin ne kaže afinitete do receptorjev za nevrotransmiterje, vključno z muskarinskim holinergičnim receptorjem za muskarin, α adrenergičnimi receptorji ali histaminergičnimi receptorji H1 ter nima neposrednih učinkov na srce.
EXP {month/year} Once opened, use by…. 
EXP {mesec/leto} Odprto zdravilo uporabite do ...
Medicines should not be disposed of via wastewater or household waste. 
Ne odvrzite zdravila v odpadne vode ali v gospodinjske odpadke.
The tablets are flavoured and most dogs will consume the tablet when offered by the owner. 
Tablete imajo dodan okus in večina psov bo z veseljem pojedla tableto, ki mu jo bo dal lastnik.
Following the last dose administration, fluoxetine and norfluoxetine plasma levels declined steadily in a log-linear fashion. 
Po zadnjem odmerku sta se stopnji fluoksetina in norfluoksetina v plazmi hitro linearno znižali.
As a result of inhibiting serotonin uptake, fluoxetine enhances serotonergic neurotransmission and produces functional effects resulting from increased activation of serotonin receptors. 
Zaradi zaviranja prisvajanja serotonina fluoksetin pospešuje delovanje serotogenih transmiterjev in povzroča funkcionalne učinke zaradi povečanega delovanja receptorjev za serotonin.
Accumulation of fluoxetine and norfluoxetine occurred following multiple doses until reaching a steady-state within approximately 10 days. 
Do akumulacije fluoksetina in norfluoksetina je prišlo po dajanju več odmerkov, ta je dosegla stalno raven v približno 10 dneh.
Reconcile should be administered orally at a once daily dose of 1 to 2 mg/kg bodyweight according to the dosage table below: 
Zdravilo Reconcile se daje peroralno z dnevnimi odmerki od 1 do 2 mg na kg telesne mase v skladu s spodnjo tabelo:
- Panting, seizures, vomiting (rare). 
- Sopenje, napadi krčev, bruhanje (redki).
And 
IN
- Decreased appetite (including anorexia); lethargy (including calmness and increased sleeping) (very common) - Urinary tract disorders (such as bladder infections, irregular urination, discomfort in passing urine); central nervous system signs (incoordination, disorientation) (common) - Weight loss/loss of condition; dilation of the pupils of the eye (uncommon) - Panting, seizures, vomiting (rare) 
- Zmanjšan tek (vključno z anoreksijo); letargija (vključno z mirnostjo in povečano zaspanostjo) (zelo pogosti) - Motnje urinarnega trakta (okužbe mehurja, neredno uriniranje, boleče uriniranje); motnje centralnega živčnega sistema (nekoordiniranost gibov, izguba orientacije) (pogosti) - Hujšanje oziroma izguba kondicije; širjenje očesnih zenic (manj pogosti)
Reconcile should not be given concomitantly with veterinary medicinal products that lower the seizure threshold (e.g. phenothiazines such as acepromazine or chlorpromazine). 
Zdravilo Reconcile se ne sme dajati sočasno z veterinarskimi zdravili, ki znižajo prag za napade krčev (npr. fenotiazini, kot sta acepromazin ali klorpromazin).
Norfluoxetine Cmax and AUC were generally dose proportional but these values were 3 to 4 fold higher on day 21 than on day 1. 
Vrednosti norfluoksetina Cmax in AUC so bile večinoma sorazmerne z odmerkom, pri čemer so bile 21. dan 3- do 4-krat višje kot 1. dne.
In clinical studies these side effects were stopped immediately upon intravenous administration of a standard dose of diazepam. 
V kliničnih študijah so neželeni učinki takoj izginili po endovenoznem dajanju standardnega odmerka diazepama.
Adverse reactions as described above, including seizures, are more common after overdose. 
Zgoraj opisani neželeni učinki, vključno z napadi krčev, so pogostejši pri prevelikem odmerku.
The tablets are packaged in HDPE bottles, each bottle containing 30 tablets with a cotton coiler and desiccant canister. 
Tablete so pakirane v plastenke iz HDPE; ena plastenka vsebuje po 30 tablet, kosem vate in sušilno sredstvo.
Shelf-life after first opening the container: 30 days. 
Rok uporabnosti po prvem odpiranju vsebnika: 30 dni.
The safety of the veterinary medicinal product has not been established during pregnancy and lactation, thus the use is not recommended during pregnancy and lactation. 
Varnost zdravila v obdobju brejosti in laktacije ni bila ugotovljena, zato uporaba zdravila ni priporočljiva v obdobju brejosti in laktacije.
Fluoxetine is metabolised to norfluoxetine, an equipotent SSRI that contributes to the efficacy of the veterinary medicinal product. 
Fluoksetin se presnavlja v norfluoksetin, ki je enako učinkovit SSRI in prispeva k učinkovitosti veterinarskega zdravila.